A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Melanoma

Trial Details

NCT ID

NCT07288203

Phase

PHASE2

Sponsor

Iovance Biotherapeutics, Inc.

Status

RECRUITING

Cancer Type

Melanoma

Locations (sample)

• Nashville, Tennessee, United States
• Greenslopes, Queensland, Australia
• Toronto, Ontario, Canada, Canada
• Montral, Quebec, Canada, Canada
• London, United Kingdom

Key Eligibility Criteria

• Participant has a histologically or pathologically confirmed diagnosis of Stage IIIC, IIID, or IV unresectable or metastatic melanoma.
• The participant has an ECOG performance status of 0 or 1 and an estimated life expectancy of \> 6 months.
• The participant must have experienced radiographic disease progression on: 1 prior line of an anti-PD-(L)1 treatment (as a monotherapy or as part o…
• Participant is assessed as having at least one resectable lesion (or aggregate lesions) for lifileucel generation.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.